Evidence map›Paper›PMID 39400371›Full record

ArticleMolecular carcinogenesis2025

Integrating Multi-Omics Data to Uncover Prostate Tissue DNA Methylation Biomarkers and Target Genes for Prostate Cancer Risk.

Shuai Liu, Jingjing Zhu, Dylan Green, Hua Zhong, Quan Long, Chong Wu, Liang Wang, Youping Deng, Lang Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular carcinogenesis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shuai LiuCancer Epidemiology Division, Population Sciences in the Pacific Program, University of Hawai'i Cancer Center, University of Hawai'i at Mānoa, Honolulu, Hawaii, USA.ORCID 0000-0003-2244-2216
Jingjing ZhuDepartment of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawai'i at Mānoa, Honolulu, Hawaii, USA.
Dylan GreenCancer Epidemiology Division, Population Sciences in the Pacific Program, University of Hawai'i Cancer Center, University of Hawai'i at Mānoa, Honolulu, Hawaii, USA.
Hua ZhongCancer Epidemiology Division, Population Sciences in the Pacific Program, University of Hawai'i Cancer Center, University of Hawai'i at Mānoa, Honolulu, Hawaii, USA.ORCID 0000-0002-9358-1582
Quan LongDepartment of Biochemistry & Molecular Biology, University of Calgary, Calgary, Alberta, Canada.
Chong WuDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Liang WangDepartment of Tumor Biology, Moffitt Cancer Center, Tampa, Florida, USA.ORCID 0000-0002-9364-8572
Youping DengDepartment of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawai'i at Mānoa, Honolulu, Hawaii, USA.
Lang WuCancer Epidemiology Division, Population Sciences in the Pacific Program, University of Hawai'i Cancer Center, University of Hawai'i at Mānoa, Honolulu, Hawaii, USA.ORCID 0000-0001-9938-3627

Funding

Pacific Center for Genome ResearchU54HG013243 · NHGRI · UNIVERSITY OF HAWAII AT MANOA · PI Youping Deng · 2023 to 2026
$10.8M
Uncovering causal protein markers to improve prostate cancer etiology understanding and risk prediction in Africans and EuropeansR01CA263494 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI Chong Wu, Lang Wu · 2022 to 2026
$3.5M
NCI NIH HHS R01 CA263494NHGRI NIH HHS U54 HG013243This study is supported by the University of Hawai'i Cancer Center, NCI R01 CA263494 (National Cancer Institute), and NHGRI/NIMHD U54 HG013243 (National Human Genome Research Institute).
6 · The paper itself

Abstract

Previous studies have indicated that specific CpG sites may be linked to the risk of prostate cancer (PCa) by regulating the expression of PCa target genes. However, most existing studies aim to identify DNA methylation (DNAm) biomarkers through blood tissue genetic instruments, which impedes the identification of relevant biomarkers in prostate tissue. To identify PCa risk-associated CpG sites in prostate tissue, we established genetic prediction models of DNAm levels using data from normal prostate samples in the GTEx (N = 108) and assessed associations between genetically predicted DNAm in prostate and PCa risk by studying 122,188 cases and 604,640 controls. We observed significant associations for 3879 CpG sites, including 926 at novel genomic loci. Among them, DNAm levels of 80 CpG sites located at novel loci are significantly associated with expression levels of 45 neighboring genes in normal prostate tissue. Of these genes, 11 further exhibit significant associations with PCa risk for their predicted expression levels in prostate tissue. Intriguingly, a total of 31 CpG sites demonstrate consistent association patterns across the methylation-gene expression-PCa risk pathway. Our findings suggest that specific CpG sites may be related to PCa risk by modulating the expression of nearby target genes.

Indexed as

Biomarkers, TumorCpG IslandsDNA MethylationProstatic NeoplasmsCase-Control StudiesGene Expression Regulation, NeoplasticGenetic Predisposition to DiseaseGenomicsHumansMaleMultiomicsProstateRisk FactorsBiomarkers, TumorassociationDNA methylationgene expressionprostate cancer

Identifiers

PMID39400371
PMCPMC12009774

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.